[go: up one dir, main page]

UY33116A - INHIBITORS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN - Google Patents

INHIBITORS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN

Info

Publication number
UY33116A
UY33116A UY33116A UY33116A UY33116A UY 33116 A UY33116 A UY 33116A UY 33116 A UY33116 A UY 33116A UY 33116 A UY33116 A UY 33116A UY 33116 A UY33116 A UY 33116A
Authority
UY
Uruguay
Prior art keywords
inhibitors
prostate specific
specific membrane
membrane antigen
antigen
Prior art date
Application number
UY33116A
Other languages
Spanish (es)
Inventor
Gustavo Fischer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY33116A publication Critical patent/UY33116A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY33116A 2009-12-18 2010-12-17 INHIBITORS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN UY33116A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075562A EP2338892A1 (en) 2009-12-18 2009-12-18 Prostate specific membrane antigen inhibitors

Publications (1)

Publication Number Publication Date
UY33116A true UY33116A (en) 2011-07-29

Family

ID=42199218

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33116A UY33116A (en) 2009-12-18 2010-12-17 INHIBITORS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN

Country Status (12)

Country Link
US (1) US20120328518A1 (en)
EP (2) EP2338892A1 (en)
JP (1) JP2013514317A (en)
KR (1) KR20120109560A (en)
CN (1) CN102741264A (en)
AR (1) AR080574A1 (en)
AU (1) AU2010332841A1 (en)
CA (1) CA2785064A1 (en)
SG (1) SG181728A1 (en)
TW (1) TW201130515A (en)
UY (1) UY33116A (en)
WO (1) WO2011073286A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104225A1 (en) * 2011-01-31 2012-08-09 Bayer Pharma Aktiengesellschaft Derivatization of radiopharmaceuticals
JP6164211B2 (en) * 2012-03-30 2017-07-19 Jsr株式会社 Photoresist composition for immersion exposure
US10065985B2 (en) 2015-02-03 2018-09-04 The Regents Of The University Of California Method for fully automated synthesis of 16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT)
PL3356385T3 (en) * 2015-09-30 2021-06-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
US11865104B2 (en) * 2017-11-29 2024-01-09 The Cleveland Clinic Foundation Antitumor TET2 modulating compounds
JP7298836B2 (en) * 2018-06-22 2023-06-27 ダイキン工業株式会社 Method for producing fluorine-containing compound
WO2025167998A1 (en) * 2024-02-06 2025-08-14 北京昌平实验室 Psma-targeting conjugate having phosphonate backbone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19522703A1 (en) 1995-06-22 1997-01-02 Bayer Ag Process for the preparation of 2-fluoro-isobutyric acid alkyl esters
JP2809145B2 (en) 1995-08-03 1998-10-08 ダイキン工業株式会社 18F-labeled fluorinated choline compound, method for producing the same, and application as a diagnostic reagent for positron tomography
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
ID18382A (en) 1996-09-27 1998-04-02 Guilford Pharm Inc PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS
WO1998053812A1 (en) 1997-05-27 1998-12-03 Guilford Pharmaceuticals Inc. Inhibitors of naaladase enzyme activity
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US6630125B2 (en) 2000-04-28 2003-10-07 Duke University 18F-labeled choline analogs
WO2001091738A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
AU6661901A (en) 2000-05-30 2001-12-11 Guilford Pharm Inc Naaladase inhibitors for treating retinal disorders and glaucoma
WO2003060523A1 (en) 2002-01-10 2003-07-24 Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
WO2004078180A2 (en) 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
US7696185B2 (en) 2006-03-14 2010-04-13 Cancer Targered Technology LLC Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
JP5529540B2 (en) * 2006-11-01 2014-06-25 ピラマル イメージング ソシエテ アノニム [F-18] -labeled L-glutamic acid, [F-18] -labeled L-glutamine, derivatives thereof, and their use and methods for their preparation
PT3699162T (en) 2006-11-08 2022-10-11 Molecular Insight Pharm Inc Heterodimers of glutamic acid
EP2921482B1 (en) 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents

Also Published As

Publication number Publication date
US20120328518A1 (en) 2012-12-27
WO2011073286A1 (en) 2011-06-23
CN102741264A (en) 2012-10-17
AR080574A1 (en) 2012-04-18
EP2513121A1 (en) 2012-10-24
JP2013514317A (en) 2013-04-25
EP2338892A1 (en) 2011-06-29
CA2785064A1 (en) 2011-06-23
SG181728A1 (en) 2012-07-30
TW201130515A (en) 2011-09-16
AU2010332841A8 (en) 2012-07-19
KR20120109560A (en) 2012-10-08
AU2010332841A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
PT2406284T (en) ANTI-BCMA ANTIBODIES
EP2421432A4 (en) MORE LEAD-MAPPING SYSTEM
EP2513299A4 (en) DECELLULATED ADIPOSIVE TISSUE
BR112012005146A2 (en) photobioreactor
BR112012013432A2 (en) transducer set
EP2598784A4 (en) PIPE SUPPORT
IT1395441B1 (en) MAGNETO-DYNAMIC TRANSDUCER WITH CENTRAL SYSTEM
BR112012007260A2 (en) bottle of water
LT2313364T (en) METHODS FOR THE DETERMINATION OF SYMMETRIC DIMETHYLARGININ
EP2516615A4 (en) IMPROVED BIOREACTORS
EP2392920A4 (en) INTERCONNECTS
DE112010002724A5 (en) diaphragm valve
BRPI1016165A2 (en) water source.
FI20095396A7 (en) Vessel
NO20091269L (en) Dynamic flange clamp
EP2378176A4 (en) PIPE CONNECTION
BRPI1009018A2 (en) photobioreactor
EP2440937A4 (en) DIAGNOSTIC PROCEDURE
EP2388861A4 (en) INTERCONNECTS
UY33116A (en) INHIBITORS OF THE PROSTATE SPECIFIC MEMBRANE ANTIGEN
EP2382909A4 (en) ENDOSCOPE SYSTEM
DK2429726T3 (en) Piping
FI20095577A0 (en) Liquid distribution hardware
DK2491292T3 (en) double Pipe System
BRPI1015272A2 (en) Fermentation

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127